The drug, Hetlioz, is designed to treat Non-24-Hour
Sleep-Wake Disorder, or Non-24, a condition that is common among the
totally blind, which can cause disrupted nighttime sleep patterns
and excessive daytime sleepiness.
Vanda's shares rose 8.1 percent to $14.15 in afternoon trading after
initially rising as high as $15.59 on the news.
(Reporting by Toni Clarke in Washington;
editing by Bernadette Baum)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.